Convatec Share Chat (CTEC)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Convatec	LSE:CTEC	London	Ordinary Share	GB00BD3VFW73	ORD 10P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-2.30p	-1.39%	162.80p	161.45p	161.80p	166.60p	158.95p	165.50p	5,260,764	16:35:27

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	1,306.5	121.4	5.9	26.0	3,177.00

Convatec Share Discussion Threads

Showing 301 to 324 of 325 messages

Chat Pages: 13 12 11 10 9 8 7 6 5 4 3 2 Older

Date	Subject	Author	Discuss
30/10/2018 09:55	Numis upgrades Convatec to ‘buy’ Numis has upgraded medical technology company Convatec (CTEC) after an ‘unwarranted’ 35% fall in the share price. Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘buy’ with a target price of 220p on the shares, which jumped 5.6% to 155p yesterday. ‘We do not think the loss of a chief executive and the decline in infusion devices warranted a 35% fall in Convatec’s share price, especially when the broader chronic care business is maintaining consistent 2% quarterly growth,’ he said. ‘We see full-year 2018 results, details on the self-help strategy and full-year 2019 outlook as key catalysts. The company trades on 10x enterprise value/earnings and offering sector leading free cashflow yield and so we upgrade to “buy”.’ HTTPS://citywire.co.uk/money/the-expert-view-just-eat-hsbc-and-iag/a1170201?re=59360&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&utm_campaign=BulkEmail_Money_Daily#i=6	philanderer	Read Full Thread Reply
26/10/2018 17:24	Detail.. Medical products and technologies company ConvaTec fell on Friday as UBS downgraded the stock to 'neutral' from 'buy' and slashed the target price to 150p from 250p, pointing to a slowdown in the wound market - to which the group is over-exposed - and limited progress in the ostomy turnaround. In addition, the bank highlighted concerns that EBIT margins will continue to decline, as investments are likely still required in internal controls, marketing and R&D, as well as capex. UBS said it expects just 2% group organic sales growth in all future periods. "We assume structural market share loss in Ostomy, with a 1% sales compound annual growth rate, ignoring significant investments aimed at delivering market growth of 5%. We also assume margins decline a further 100 basis points before stabilising at 22.5% from 2020, ignoring guidance of upside from 2020 from operating leverage and margin strategy to be announced in February 2019." In its upside scenario, UBS sees fair value at 240p a share. However, without a CEO and after high senior staff turnover since IPO, it's hard to get comfort execution issues won't continue, it said. Earlier this month, ConvaTec shares tumbled as it issued a profit and announced that CEO Paul Moraviec was stepping down. HTTPS://uk.webfg.com/news/broker-recommendations-/broker-tips-convatec-burberry--3562829.html	philanderer	Read Full Thread Reply
26/10/2018 08:37	Downgrade from UBS 'neutral' from 'buy' ... TP 150p cut from 250p	philanderer	Read Full Thread Reply
25/10/2018 08:56	Peel Hunt 'hold' tp 170p cut from 220p	philanderer	Read Full Thread Reply
22/10/2018 10:34	ConvaTec Group, down 3.0%. HSBC downgraded the wound dressings maker to Hold from Buy. Target 165p cut from 245p	philanderer	Read Full Thread Reply
19/10/2018 20:36	Thanks giardap.	erogenous jones	Read Full Thread Reply
19/10/2018 20:18	You could get free samples from the other companies to try whilst running down your prescription. I need to declare I currently work for a UK manufacturer and 15 yrs ago used to work for ConvaTec R&D.	giardap	Read Full Thread Reply
19/10/2018 18:49	Erogenous, get your Stoma Nurse to source alternative products for you to try. There are a number of manufacturers out there in the UK.	giardap	Read Full Thread Reply
18/10/2018 20:15	I use their products. For the most part they provide dignity and a totally normal life. There are occasinal leaks, but fewer each year. This means that the product remains dynamic and evolving. So that you understand what I am wittering about, I have an ileostomy which is permanent and the product I use, is, I stress, a market leader. However, there have been difficulty in supply over the last 9 months. I gather that this has been addressed. In practice, the product that I have used for the last 10 years has been discontinued. Its replacement has been used for the last 3 weeks. It is unsatisfactory. A replacement is being investigated. Patients like advances that are beneficial not superficial. What is wrong with it? The closure system. Two catastrophic failures in as many weeks compared with one in the last 10 years.... co-incidence, perhaps?	erogenous jones	Read Full Thread Reply
18/10/2018 19:53	Bought today at £1.49 - prepared to sit and wait.Ageing society - a good long term buy. Unfortunatately this company was "fleeced" prior to and ramped at IPO by PE owners. Hopefully as their influence dwindles ConvaTec can get on with running its business with more attention to detail.	giardap	Read Full Thread Reply
18/10/2018 07:56	directors bought before the drop paying 220p ish a share	trjones2	Read Full Thread Reply
16/10/2018 09:30	Director Buys - Finance Director yesterday and Senior Non Exec today - they are certainly very confident	nerdofsteel	Read Full Thread Reply
16/10/2018 09:18	210p, 183p, 165p all greater than the current 155p at least	nerdofsteel	Read Full Thread Reply
16/10/2018 08:47	Downgraded by JP Morgan Caz to 'neutral' ... tp 183p cut from 303p Downgraded by Goldmans to 'neutral' ... tp 165p cut from 255p	philanderer	Read Full Thread Reply
16/10/2018 08:37	RBC retains 'outperform' ... target 210p cut from 240p	philanderer	Read Full Thread Reply
16/10/2018 07:25	from Citywire Buying opportunity at Convatec, says Numis Medical technology company Convatec (CTEC) has delivered a poor third statement but the heavy share price fall could present a buying opportunity. The shares tumbled 34% to 148.2p yesterday after the company issued a profit warning and announced the departure of chief executive Paulk Moraviec. Analyst Paul Cuddon retained his ‘hold’ recommendation and target price of 220p on the shares. ‘Ultimately the statement reads poorly, but on our first take, the earnings per share downgrade is just 5% and should the shares fall materially we could see an interesting buying opportunity with the performance of the chronic care business showing continued steady growth,’ he said.	robow	Read Full Thread Reply
16/10/2018 07:22	7% Free Cash Flow Yield. Bang on. Shorts can keep trying!	cantrememberthis2	Read Full Thread Reply
15/10/2018 23:32	Lex Column: 'ConvaTec: scar issue' Medical products group needs more time to heal itself after investors were bloodied https://www.ft.com/content/07bc74d8-d04d-11e8-a9f2-7574db66bcd5	philanderer	Read Full Thread Reply
15/10/2018 23:17	'ConvaTec shares plunge after profit warning and chief’s exit' Second profit warning in 12 months for medical equipment maker Analysts naming Medtronic as C'tecs biggest customer which has "changed it's ordering pattern of its infusion devices business" article: https://www.ft.com/content/672418a6-d041-11e8-a9f2-7574db66bcd5	philanderer	Read Full Thread Reply
15/10/2018 20:05	Back on the watchlist . Numis... 'hold' tp 220p Peel Hunt ... 'hold'	philanderer	Read Full Thread Reply
15/10/2018 19:56	From sharemagazine JP Morgan Cazenove analyst David Adlington is surprised by yet another profit warning following ‘positive commentary’ over the summer from management. He believes the new guidance implies a decline by 5% to 10% in earnings per share, but argues the valuation is still ‘attractive217; with ‘limited further downside’.	cantrememberthis2	Read Full Thread Reply
15/10/2018 19:46	Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities. "We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value."	cantrememberthis2	Read Full Thread Reply
15/10/2018 13:39	NICE - Fast reactions, even a bean counter is parting with their money at 150p/share. Game on dudes. Shorts may close, well come of them. Some DIRECTORS wait days, these boys are doing it like MICROFOCUS...so quickly.	cantrememberthis2	Read Full Thread Reply
15/10/2018 13:36	Director Buying	nerdofsteel	Read Full Thread Reply

Chat Pages: 13 12 11 10 9 8 7 6 5 4 3 2 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.